LEXICON PHARMACEUTICALS, INC.
LXRXNasdaq
$2.39
↑ +6.7%Jul 17 close · end-of-day
Price
1Y↑ +85.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$956.6M
Enterprise Value
$835.6M
P/E
—
P/S
13.7
P/B
4.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$69.6M
Net Income (TTM)
-$26.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-34.8%
Net Margin
-37.5%
ROE
-12.9%
ROIC
-23.4%
Debt / Equity
0.2
Net Cash
$121.0M
Return 1Y
+77.0%
Company profile
Lexicon Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the. treatment of neuropathic pain.
- CEO
- Lonnel Coats
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Headquarters
- Texas
- Website
- lexpharma.com
Management & directors
- Coiante Scott MSVP, Chief Financial Officer
- Crum Brian TSVP, General Counsel & Secr.
- Exton MichaelChief Executive Officer
- Gopinathan SumaSVP, Discovery
- Granowitz Craig BSVP, Chief Medical Officer
- Martens Rachel YapSVP, Partnerships & Corp Strat
- Mcdermott WendySVP, Human Resources
- UnknownSVP, IR and Corp Comm
Roles derived from SEC Form 4 filings.
Earnings
LXRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$21.1M↑ +1572.1%
Diluted EPS$0.00↓ -100.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $24.0M | $298,000.00 | $139,000.00 | $1.2M | $31.1M | $49.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$47.8M | -$87.1M | -$100.8M | -$171.8M | -$197.1M | -$48.9M |
| Net income | -$58.6M | -$87.8M | -$101.9M | -$177.1M | -$200.4M | -$50.3M |
| Diluted EPS | -$0.53 | -$0.60 | -$0.62 | -$0.80 | -$0.63 | -$0.14 |
| Operating cash flow | -$143.0M | -$87.0M | -$88.9M | -$161.9M | -$178.8M | -$67.9M |
| Free cash flow | -$143.1M | -$88.2M | -$90.2M | -$162.4M | -$179.8M | -$67.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -199.2% | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% |
| Net margin | -244.1% | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $1.8M | $26.6M | $1.3M | $28.9M | $14.2M | $5.5M | $21.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$55.4M | -$63.7M | -$32.7M | -$25.7M | $3.7M | -$12.2M | -$14.8M | -$996,000.00 |
| Net income | -$53.4M | -$64.8M | -$33.8M | -$25.3M | $3.3M | -$12.8M | -$15.5M | -$1.0M |
| Diluted EPS | -$0.17 | -$0.18 | -$0.08 | -$0.07 | $0.01 | -$0.04 | -$0.04 | $0.00 |
| Operating cash flow | -$48.5M | -$53.6M | -$21.5M | -$43.8M | $17.0M | -$23.8M | -$17.2M | -$14.7M |
| Free cash flow | -$48.8M | -$53.9M | -$22.0M | — | — | -$23.8M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -3360.9% | -3639.6% | -123.3% | -2034.8% | 12.9% | -85.9% | -269.1% | -4.7% |
| Net margin | -3244.0% | -3703.5% | -127.2% | -2004.4% | 11.3% | -90.0% | -282.7% | -4.9% |
Company news
Jun 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | Option exercise | 89,312 | $0.00 | $0.00 | filing |
| 2026-06-03 | Sullivan Diane E. | Option exercise | 89,312 | $0.00 | $0.00 | filing |
| 2026-06-03 | SOBECKI CHRISTOPHER J | Option exercise | 89,312 | $0.00 | $0.00 | filing |
| 2026-06-03 | Cheung Ivan | Option exercise | 89,312 | $0.00 | $0.00 | filing |
| 2026-06-03 | BARKER SAM L | Option exercise | 89,312 | $0.00 | $0.00 | filing |
| 2026-06-03 | Amouyal Philippe | Option exercise | 89,312 | $0.00 | $0.00 | filing |
| 2026-06-03 | DEBBANE RAYMOND | Option exercise | 89,312 | $0.00 | $0.00 | filing |
| 2026-04-30 | Artal Participations S.a r.l. | Option exercise | 20,421,735 | $0.00 | $0.00 | filing |
| 2026-02-28 | Exton Michael· Chief Executive Officer | Tax withholding | 204,831 | $1.47 | $301,101.57 | filing |
| 2026-02-28 | Granowitz Craig B· SVP, Chief Medical Officer | Tax withholding | 109,098 | $1.47 | $160,374.06 | filing |
| 2026-02-28 | Crum Brian T· SVP, General Counsel & Secr. | Tax withholding | 105,019 | $1.47 | $154,377.93 | filing |
| 2026-02-28 | Unknown· SVP, IR and Corp Comm | Tax withholding | 74,572 | $1.47 | $109,620.84 | filing |
| 2026-02-28 | McDermott Wendy· SVP, Human Resources | Tax withholding | 68,107 | $1.47 | $100,117.29 | filing |
| 2026-02-28 | Coiante Scott M· SVP, Chief Financial Officer | Tax withholding | 54,881 | $1.47 | $80,675.07 | filing |
| 2026-02-28 | Martens Rachel Yap· SVP, Partnerships & Corp Strat | Tax withholding | 35,826 | $1.47 | $52,664.22 | filing |
| 2026-02-28 | Gopinathan Suma· SVP, Discovery | Tax withholding | 24,338 | $1.47 | $35,776.86 | filing |
| 2026-02-28 | Gopinathan Suma· SVP, Discovery | Option exercise | 20,310 | — | — | filing |
| 2026-02-28 | Gopinathan Suma· SVP, Discovery | Option exercise | 65,640 | — | — | filing |
| 2026-02-28 | Unknown· SVP, IR and Corp Comm | Option exercise | 24,674 | — | — | filing |
| 2026-02-28 | Unknown· SVP, IR and Corp Comm | Option exercise | 128,190 | — | — | filing |
| 2026-02-28 | Crum Brian T· SVP, General Counsel & Secr. | Option exercise | 33,457 | — | — | filing |
| 2026-02-28 | Crum Brian T· SVP, General Counsel & Secr. | Option exercise | 69,386 | — | — | filing |
| 2026-02-28 | Crum Brian T· SVP, General Counsel & Secr. | Option exercise | 170,163 | — | — | filing |
| 2026-02-28 | Coiante Scott M· SVP, Chief Financial Officer | Option exercise | 160,237 | — | — | filing |
| 2026-02-28 | Exton Michael· Chief Executive Officer | Option exercise | 503,263 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.